Fiduciary Alliance LLC Buys 3,610 Shares of Abbott Laboratories $ABT

Key Points

• Fiduciary Alliance LLC increased its stake in Abbott Laboratories by 15.6% in Q2, acquiring an additional 3,610 shares, bringing its total holdings to 26,816 shares worth approximately $3,647,000.
• Several institutional investors have recently changed their positions in Abbott Laboratories, with 75.18% of the stock now owned by such entities, indicating strong institutional interest.
• Abbott Laboratories reported strong Q2 earnings of $1.26 per share, slightly exceeding analysts' expectations, and has set FY 2025 guidance at 5.100-5.200 EPS.

Fiduciary Alliance LLC lifted its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 15.6% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 26,816 shares of the healthcare product maker's stock after acquiring an additional 3,610 shares during the quarter. Fiduciary Alliance LLC's holdings in Abbott Laboratories were worth $3,647,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Kelly Financial Services LLC bought a new stake in Abbott Laboratories during the first quarter valued at about $216,000. Bank Pictet & Cie Europe AG boosted its stake in Abbott Laboratories by 1.9% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker's stock valued at $17,274,000 after purchasing an additional 2,774 shares during the period. Edge Financial Advisors LLC grew its holdings in Abbott Laboratories by 3.3% in the 1st quarter. Edge Financial Advisors LLC now owns 2,530 shares of the healthcare product maker's stock valued at $336,000 after buying an additional 81 shares during the last quarter. Public Employees Retirement System of Ohio bought a new position in Abbott Laboratories in the 4th quarter worth approximately $84,418,000. Finally, Cerity Partners LLC lifted its holdings in shares of Abbott Laboratories by 49.8% during the first quarter. Cerity Partners LLC now owns 1,507,268 shares of the healthcare product maker's stock worth $199,939,000 after buying an additional 501,200 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ABT has been the subject of a number of research reports. Wells Fargo & Company reduced their price target on shares of Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating for the company in a report on Friday, July 18th. Evercore ISI upped their price objective on shares of Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a research report on Tuesday, July 8th. Leerink Partnrs raised Abbott Laboratories to a "hold" rating in a research report on Monday, June 16th. Leerink Partners initiated coverage on Abbott Laboratories in a report on Monday, June 16th. They issued a "market perform" rating and a $143.00 price target for the company. Finally, William Blair raised Abbott Laboratories to a "strong-buy" rating in a report on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, Abbott Laboratories presently has a consensus rating of "Moderate Buy" and an average price target of $144.47.

Insider Buying and Selling

In other news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the sale, the chief financial officer directly owned 51,003 shares of the company's stock, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.46% of the company's stock.

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $131.40 on Tuesday. The stock has a 50-day simple moving average of $130.36 and a 200 day simple moving average of $131.21. The stock has a market capitalization of $228.70 billion, a price-to-earnings ratio of 16.47, a P/E/G ratio of 2.54 and a beta of 0.69. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. Abbott Laboratories has a 12-month low of $110.86 and a 12-month high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm had revenue of $11.14 billion during the quarter, compared to analysts' expectations of $11.01 billion. During the same quarter last year, the company posted $1.14 EPS. The company's quarterly revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.